Arcutis Biotherapeutics, Inc. (ARQT)
25.16
-0.13
(-0.51%)
USD |
NASDAQ |
Oct 02, 16:00
25.16
0.00 (0.00%)
After-Hours: 20:00
Arcutis Biotherapeutics Gross Profit Margin (Quarterly) : 91.58% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.58% |
| March 31, 2026 | 90.72% |
| December 31, 2025 | 90.97% |
| September 30, 2025 | 91.25% |
| June 30, 2025 | 90.81% |
| March 31, 2025 | 86.59% |
| December 31, 2024 | 90.32% |
| September 30, 2024 | 87.70% |
| Date | Value |
|---|---|
| June 30, 2024 | 88.77% |
| March 31, 2024 | 93.43% |
| December 31, 2023 | 81.93% |
| September 30, 2023 | 96.37% |
| June 30, 2023 | 79.54% |
| March 31, 2023 | 71.84% |
| December 31, 2022 | 75.45% |
| September 30, 2022 | 30.34% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Insmed, Inc. | 83.71% |
| Emergent BioSolutions, Inc. | 51.22% |
| Exelixis, Inc. | 96.71% |
| Puma Biotechnology, Inc. | 77.92% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 15.90% |
| Return on Assets | 6.77% |
| Return on Invested Capital | 9.74% |
| Profit Margin (Quarterly) | 11.56% |
| Operating Margin (Quarterly) | 12.65% |
| Return on Net Operating Assets | 14.61% |